Cue Biopharma Financials - Benzinga

Cue Biopharma Inc

CUENASDAQ

Trade with Public

Trade with Public

$35.16

3.5211.13%

Ult. Agg.: Sep 16, 12:53 PM

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Rapporto azionario

Cue Biopharma Financials

Cue Biopharma (CUE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share

Benzinga Newsdesk

PRO
Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.10) by 1100 percent. This is a 78.18 percent increase over losses of $(4.95) per share from the

Benzinga Newsdesk

PRO
Cue Biopharma Q4 EPS $0.01 Beats $(0.10) Estimate, Sales $21.942M Up From $1.576M Prior Year

Cue Biopharma (NASDAQ:CUE) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.10) by 110 percent. This is a 107.69 percent increase over losses of $(0.13) per share from the

Benzinga Newsdesk

PRO
Cue Biopharma Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.149M Miss $2.290M Estimate

Benzinga Newsdesk

PRO
Cue Biopharma Q2 EPS $(0.09) Beats $(0.14) Estimate, Sales $2.954M Beat $2.396M Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 55 percent increase over losses of $(0.20) per share from the

Benzinga Newsdesk

PRO
Cue Biopharma Q1 EPS $(0.17) Misses $(0.15) Estimate, Sales $421.00K Miss $1.27M Estimate

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 32 percent increase over losses of $(0.25) per share from the

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved